JTO Insights

JTO Insights: June 2026

Episode 5: In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the Journal of Thoracic Oncology June issue. Dr. Natasha B. Leighl, Head of Division of Medical Oncology and Hematology at the Princess Margaret Cancer Centre, joins us to discuss their article "Identifying patients with high-risk stage I NSCLC using tumor-informed plasma ctDNA"; and Dr. Gabriella Sozzi, who leads the Experimental Oncology Department and Epigenomics & Biomarkers of Solid Tumors Unit at National Cancer Institute in Milan, Italy, joins to discuss their article, "Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening". Recommended Reading: 1. Identifying patients with high-risk stage I NSCLC using tumor-informed plasma ctDNA: https://www.jto.org/article/S1556-0864(26)00098-5/fulltext 2. Clinical Value of Combining Molecular and Immune Blood Tests to Safely Reduce False Positives in Low-Dose CT Lung Cancer Screening: https://www.jto.org/article/S1556-0864(26)00067-5/fulltext 3. This month’s JTO issue: https://www.jto.org/issue/S1556-0864(26)X2004-4

JTO Insights: 20 Years of Advances in Screening & Surgery

In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the JTO 20th Anniversary Series. Dr. Stephen Lam, Director of the MDS-Rix Early Lung Cancer Detection and Translational Research Program at BC Cancer Research Institute, joins us to discuss their article, “A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening"; and Dr. Paul Van Schil, Consultant Thoracic Surgeon at Antwerp University Hospital, joins to discuss their article, "Journal of Thoracic Oncology 20th Anniversary Series - Surgery". Recommended Reading: JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries A Game-Changing 20 Years: Progress and Future Directions in Lung Cancer Screening: https://www.jto.org/article/S1556-0864(25)02935-1/fulltext Journal of Thoracic Oncology 20th Anniversary Series - Surgery: https://www.jto.org/article/S1556-0864(25)02938-7/fulltext

JTO Insights: May 2026

In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the May issue of the Journal of Thoracic Oncology. Dr. Bonnie Ky, Founder’s Professor of Cardio-Oncology at the Perelman School of Medicine, University of Pennsylvania, discusses their article “Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer”; and Dr. David Planchard, Head of Thoracic Group at Gustave Roussy, discusses their article “Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial.” Guests: Bonnie Ky, MD, MSCE Founders Professor of Cardio-Oncology, Division of Cardiovascular Medicine Senior Scholar, Center for Clinical Epidemiology and Biostatistics Director, Thalheimer Center for Cardio-Oncology, Director, Penn Center for Quantitative Echocardiography Perelman School of Medicine at the University of Pennsylvania, United States. Dr. David Planchard is a thoracic oncologist and head of Thoracic Group at Gustave Roussy, where he is responsible for coordinating the care of patients with lung cancer, pleural mesothelioma and thymic tumors. He is also Chairman of the International Centre for Thoracic Cancers (CICT), a health cooperation consortium involving Gustave Roussy, Hôpital Marie-Lannelongue and Hôpital Paris Saint-Joseph. Recommended Reading: Changes in Cardiac Function in Patients Receiving Radiation Therapy for Lung Cancer: https://www.jto.org/article/S1556-0864(26)00002-X/fulltext Trastuzumab Deruxtecan in Patients with HER2-Overexpressing Non-Small Cell Lung Cancer: Results From Part 1 of the Open-label, Multicenter, Phase 1b DESTINY-Lung03 Trial: https://www.jto.org/article/S1556-0864(25)03021-7/fulltext JTO May 2026 Issue: https://www.jto.org/issue/S1556-0864(26)X2003-2

JTO Insights: 20 Years of Advances in Basic Science & Radiotherapy

In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the JTO 20th Anniversary Series. Dr. Michele Carbone, Director of the Thoracic Oncology Program at the University of Hawaii Cancer Center, joins us to discuss their article, “Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact"; and Dr. Jeff Bogart, Distinguished Professor and Chair of Radiation Oncology of SUNY Upstate Medical University, New York, joins to discuss their article, "The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress". Recommended Reading: JTO 20th Anniversary Series: https://www.jto.org/content/20thAnniversarySeries "Advances in the Basic Sciences in Thoracic Oncology in the Last 20 Years and Their Translational Impact": https://www.jto.org/article/S1556-0864(25)02895-3/fulltext "The Optimization of Radiotherapy in Lung Cancer Treatment: 20 Years of Progress": https://www.jto.org/article/S1556-0864(26)00031-6/fulltext

JTO Insights: April 2026

In this episode of JTO Insights, Editor-in-Chief Dr. Alex Adjei and Associate Editor Dr. Tom John host authors of two articles published in the Journal of Thoracic Oncology April 2026 issue. Dr. Timothy F. Burns, Professor of Medicine in the Division of Medical Oncology at the Ohio State University Comprehensive Cancer Center, joins us to discuss their article "Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC"; and Dr. Paaladinesh Thavendiranathan of Division of Cardiology, Peter Munk Cardiac Center at the Toronto General Hospital and the Director of the Ted Rogers Program in Cardiotoxicity Prevention joins to discuss their article, "The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy". Key Topics Covered: • KRAS G12C-mutant NSCLC • Thymoma • Cardiovascular adverse outcomes Recommended Reading: April 2026 JTO Issue: https://www.jto.org/issue/S1556-0864(26)X2002-0 "Efficacy and Safety of Olomorasib in Combination with Pembrolizumab in Treatment of Patients with KRAS G12C-Mutant Advanced NSCLC": https://www.jto.org/article/S1556-0864(25)02936-3/fulltext "The risk of cardiovascular adverse outcomes in patients with thymoma or thymic carcinoma receiving cancer therapy": https://www.jto.org/article/S1556-0864(25)02940-5/fulltext